P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)

ABSTRACT:

SUBMITTER: Gupta V 

PROVIDER: S-EPMC9431359 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature